Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.

Press Release – Lilly and the JDRF Partner to Fund Regenerative Medicine Research in Type 1 Diabetes

INDIANAPOLIS and NEW YORK – Eli Lilly and Company and the Juvenile Diabetes Research Foundation (JDRF) today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin -producing cells destroyed by the disease.